Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer
Neal D. Shore, Raluca Ionescu‐Ittu, Lingfeng Yang, François Laliberté, Malena Mahendran, Dominique Lejeune, Louise Yu, Joseph E. Burgents, Mei Sheng Duh, Sameer R. Ghate
Abstract
Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.